Short answer
Danaher Corporation (DHR) filed its Q1 2026 10-Q quarterly report on Apr 21, 2026 for the quarter ended Mar 27, 2026. Quarterly revenue was $6.0B (up 3.7% year over year) with net income of $1.0B.
Q1 2026 key financials · XBRL
- Revenue
- $6.0B
- +3.7% YoY
- Net income
- $1.0B
- +7.9% YoY
- Operating margin
- 22.6%
- Gross margin
- 60.3%
- EPS (diluted)
- $1.45
- +9.8% YoY
Source: XBRL data from the Danaher Corporation (DHR) Q1 2026 10-Q on SEC EDGAR. USD.
Danaher Corporation Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $5.951B, up 3.5% YoY from $5.741B; core sales up 0.5%
- Operating margin 22.6% vs 22.2% YoY; net earnings approximately $1.0B vs $954M
- Biotechnology best performer: sales $1.797B, up 11.5%; operating margin 29.7% vs 27.4%
- Diagnostics weakest: sales $2.417B vs $2.449B; core sales declined
- Tariff impacts immaterial; Middle East conflict caused delivery delays and higher logistics costs
Risk Factors
- Newly added military-conflict risk triggered by Middle East hostilities beginning and escalating in February 2026
- Most material update: conflict-related energy and supply-chain disruptions increased costs and capital-market volatility
- Regulatory risk from sanctions and embargoes related to military conflicts
- Operational risk from supply-chain disruptions and increased energy and other supply costs
- Financial risk from capital-markets dislocation and volatility affecting financial statements
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Danaher Corporation quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.